Safeway, Theranos split after $350 million deal fizzles | Wall Street Journal
The grocery giant spent $350 million building clinics to offer Theranos blood tests in more than 800 of its stores, but testing never began, and the companies are now negotiating an end to the deal, insiders told the Wall Street Journal. Theranos missed deadlines for the rollout, and Safeway had concerns over the accuracy of Theranos test results provided to Safeway employees tested at the chain's headquarters.
FDA sends letter to DNA4Life over consumer gene tests | Reuters
DNA4Life, a newer player in the direct-to-consumer testing game that sells kits to predict patient response to drug treatments, got a warning letter (PDF) from the FDA for failing to get the agency's approval before marketing, Reuters reports.
The start-up that will keep health insurance companies honest | The Atlantic
Two Harvard mathematicians have launched a startup, HoneyInsured, to help consumers choose the right health plan through HealthCare.gov by allowing them to comparison shop using data on pricing, network size, deductible vs. premium visualizations, and cost scenarios for various conditions.
Popular heart surgery carried hidden danger | STAT
Physicians have been performing cardiac surgery to treat atrial fibrillation with a device never intended or approved for use in the heart. A STAT investigation shows many patients have subsequently suffered injury or death. Some say the device reveals gaps in the FDA's fast-track approval process.
Doctor treats homebound patients, often unseen even by neighbors | NPR
An NPR photo essay offers an intimate look into the life of a physician who treats homebound patients in upstate New York.
